JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, J. W.
Right arrow Articles by Sheffy, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, J. W.
Right arrow Articles by Sheffy, D. H.

Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin

JW Ryan, P Berryer, AY Chung and DH Sheffy

Department of Medicine, University of Miami School of Medicine, Florida.

The nonapeptide bradykinin (BK) is hydrolyzed at multiple sites during a single passage through the rat pulmonary vascular bed. Hydrolysis of one bond, Arg1-Pro2, appears to be catalyzed by an aminoacylproline hydrolase called aminopeptidase P (AmP). To help clarify its role in BK degradation, we have characterized rat pulmonary AmP in vivo in terms of its ability to react with intravascular substrates, its saturability and its contributions to the inactivation of circulating BK. By using indicator dilution methodology, hydrolysis of tracer doses of the AmP substrate Arg-Pro-Pro-[3H]benzylamide ([3H]APPB) during a single transit through the pulmonary vascular bed was measured. Transpulmonary hydrolysis of [3H]APPB obeyed first-order enzyme kinetics and was inhibited by carrier substrate (APPB) and two alternative AmP substrates, BK and des-Arg9-BK. APPB, des-Arg9-BK and des-Arg1-BK, all capable of binding to AmP in vitro, potentiated hypotensive effects of BK injected i.v. A saturating dose of APPB, 2 mumol/kg, in coinjections with BK, potentiated effects of i.v. BK by about 4-fold when pulmonary angiotensin converting enzyme (ACE) was active or inhibited completely. Complete inhibition of ACE potentiated blood pressure effects of i.v. BK by 40- to 120-fold. When both AmP and ACE were inhibited, the effects of i.v. BK were potentiated by up to 800-fold, and the hypotensive effects of BK injected i.v. on systemic mean arterial blood pressure were equivalent to effects of BK injected into the ascending aorta (i.a.); the BK i.v. and i.a. log dose-response curves were virtually superimposable.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 269, Issue 3, pp. 941-947, 06/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
HypertensionHome page
J. Lefebvre, L. J. Murphey, T. V. Hartert, R. Jiao Shan, W. H. Simmons, and N. J. Brown
Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema
Hypertension, February 1, 2002; 39(2): 460 - 464.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. J. Murphey, D. L. Hachey, J. A. Oates, J. D. Morrow, and N. J. Brown
Metabolism of Bradykinin In Vivo in Humans: Identification of BK1-5 as a Stable Plasma Peptide Metabolite
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 263 - 269.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
K.-S. Kim, S. Kumar, W. H. Simmons, and N. J. Brown
Inhibition of Aminopeptidase P Potentiates Wheal Response to Bradykinin in Angiotensin-Converting Enzyme Inhibitor-Treated Humans
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 295 - 298.
[Abstract] [Full Text]


Home page
HypertensionHome page
A. Dendorfer, S. Wolfrum, U. Schafer, J. M. Stewart, N. Inamura, and P. Dominiak
Potentiation of the Vascular Response to Kinins by Inhibition of Myocardial Kininases
Hypertension, January 1, 2000; 35(1): 32 - 37.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S.-I. Kitamura, L. A. Carbini, W. H. Simmons, and A. G. Scicli
Effects of aminopeptidase P inhibition on kinin-mediated vasodepressor responses
Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1664 - H1671.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
F. Marceau, J. F. Hess, and D. R. Bachvarov
The B1 Receptors for Kinins
Pharmacol. Rev., September 1, 1998; 50(3): 357 - 386.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M.-J. Dumoulin, A. Adam, C. Blais Jr., and D. Lamontagne
Metabolism of bradykinin by the rat coronary vascular bed
Cardiovasc Res, April 1, 1998; 38(1): 229 - 236.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Blais Jr., G. Drapeau, P. Raymond, D. Lamontagne, N. Gervais, I. Venneman, and A. Adam
Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study
Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2263 - H2271.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Hauser, J. Strassner, and A. Schaller
Cloning, Expression, and Characterization of Tomato (Lycopersicon esculentum) Aminopeptidase P
J. Biol. Chem., August 17, 2001; 276(34): 31732 - 31737.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics.